Loading
A phase 3 trial of capecitabine, fOLFOX (5-FU, leucovorin, oxaliplatin) and fOLFIRINOX / mFOLFIRINOX in colorectal cancer, run by UNICANCER, active but no longer recruiting.
Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test is a phase 3, randomised interventional study registered as NCT07340567 by UNICANCER, with a registry enrolment figure of 2450 participants, started 2026-07-20 and due to reach its primary completion in 2032-11-01. Interventions recorded: Capecitabine; Oxaliplatin; Folfirinox; FOLFOX regimen. Conditions listed: Colorectal Cancer. Primary outcome: Non-inferiority of 6-month CAPE vs 3-month CAPOX ACT in terms of 3-year Disease Free Survival ctDNA-negative cohort; Superiority of 6-month FOLFIRINOX vs 6-month FOLFOX ACT in terms of 3-year Disease Free Survival ctDNA-positive cohort. Colorectal eligibility wording from the registry: "Histologically confirmed stage III pMMR/MSS colon and high rectum adenocarcinoma (T, N1 or N2, M0) excluding medium and low rectal cancers (≥12 cm from the anal verge by endoscopy and/or above the peritoneal reflection at surgery are still eligible), without gross or microscopic evidence of residual". Sites: France, Sweden. No results are recorded here; the registry entry is the source.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), MRD / molecular residual disease testing, Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), MRD / molecular residual disease testing, Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), MRD / molecular residual disease testing, Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.